A microdose of semaglutide typically refers to doses below the standard 0.25 mg weekly starting dose — often 0.05 to 0.1 mg weekly. The term is informal and not FDA-defined. Microdoses are only available through compounded semaglutide because brand-name pens do not deliver doses below 0.25 mg. Microdosing is sometimes used by patients with severe side-effect intolerance or anxiety about starting; the goal is acclimation rather than meaningful weight loss.
Typical Microdose Ranges
“Microdose” is not a precise term, but commonly refers to:
- Very low microdose: 0.05 mg weekly
- Low microdose: 0.1 mg weekly
- Sub-therapeutic: 0.125 mg or 0.15 mg weekly
- Standard starting dose: 0.25 mg weekly
Any dose below 0.25 mg is technically a microdose by this convention. The standard 0.25 mg is itself a low dose — it’s the starting dose, not a therapeutic dose.
Why Microdose?
Patients and prescribers sometimes choose to start below the standard 0.25 mg for several reasons:
Severe side-effect sensitivity. Some patients experience severe nausea even at the 0.25 mg starting dose. Microdosing acclimates the body more gently, reducing the intensity of GI symptoms.
Past adverse experience. Patients who have previously discontinued GLP-1 drugs due to side effects may want to try again with a gentler ramp.
Anxiety about starting. Some patients are nervous about side effects and prefer to start at a “barely there” dose to confirm they tolerate the drug.
Specific comorbidities. Patients with eating disorders history, gastroparesis, or other conditions where rapid GLP-1 effects could be problematic may benefit from gentler escalation.
Clinician preference. Some prescribers use very slow titration as a routine approach for all patients.
Microdose Volume Calculations
At common compounded concentrations:
| Dose | Volume at 2.5 mg/mL | Units (U-100 syringe) |
|---|---|---|
| 0.05 mg | 0.02 mL | 2 units |
| 0.10 mg | 0.04 mL | 4 units |
| 0.125 mg | 0.05 mL | 5 units |
| 0.15 mg | 0.06 mL | 6 units |
| 0.20 mg | 0.08 mL | 8 units |
| 0.25 mg (standard start) | 0.10 mL | 10 units |
At these very small volumes (2-4 units), a 0.3 mL low-dose insulin syringe with finer markings provides better measurement precision than a standard 1 mL syringe.
What Microdosing Produces
Realistic expectations:
- Side effects: Substantially milder than standard dosing. Many patients tolerate microdoses with no GI symptoms.
- Appetite suppression: Minimal at very low doses. Some patients notice subtle effects; others notice nothing.
- Weight loss: Minimal. The 0.25 mg standard starting dose produces only 1-3 pounds in 4 weeks; microdoses produce less.
- Blood sugar effects (for diabetes): Minimal at very low doses.
Microdosing is acclimation, not therapy. The goal is to reach standard doses (or beyond) over time. Staying at microdoses indefinitely produces little benefit.
Typical Microdose Titration Schedule
An example slower titration:
| Week | Dose |
|---|---|
| 1-2 | 0.05 mg |
| 3-4 | 0.10 mg |
| 5-6 | 0.15 mg |
| 7-8 | 0.20 mg |
| 9-12 | 0.25 mg (standard starting dose) |
| 13+ | Continue standard Wegovy titration to 2.4 mg maintenance |
This adds 12 weeks to the standard 16-week titration, for a total of about 28 weeks to reach the 2.4 mg maintenance dose. The total cost of the gentler approach is mostly time — and a higher per-month cost while making minimal progress.
Brand-Name vs Compounded for Microdosing
Brand-name pens (Ozempic, Wegovy) deliver fixed pre-measured doses. The smallest dose available in either product line is 0.25 mg. You cannot microdose with brand-name semaglutide.
Compounded semaglutide is supplied in multi-dose vials, allowing any dose volume to be drawn with an insulin syringe. This makes microdosing possible. The trade-off is that compounded semaglutide carries FDA-noted safety, quality, and dosing-error risks.
Cost of Microdosing
The drug cost per week is the same regardless of dose (since you’re paying for the vial, not per mg used). Microdosing extends the period of paying for medication without weight-loss benefit. Practical implications:
- Insurance coverage rarely benefits from microdosing (still paying full monthly cost)
- Manufacturer savings cards don’t apply to compounded semaglutide
- Extended titration time means extended cost without proportional weight loss
- Eventually reaching standard doses is necessary for therapeutic benefit
When Microdosing Doesn’t Make Sense
Microdosing may not be the best approach if:
- You tolerate the 0.25 mg starting dose without significant problems
- You have aggressive weight-loss goals and need rapid titration
- You have type 2 diabetes needing prompt glycemic control
- You can use brand-name pens at the standard 0.25 mg dose
For most patients, the standard 0.25 mg starting dose is well-tolerated and produces appropriate acclimation without needing microdoses.
Discuss with Your Prescriber
If you’re considering microdosing because of side-effect concerns, discuss with your prescriber. They can:
- Confirm microdosing is appropriate for your situation
- Write a prescription for compounded semaglutide at the appropriate concentration
- Coordinate with a compounding pharmacy that can produce the formulation
- Set up a titration schedule appropriate for your goals
- Monitor your response and adjust as needed
Self-directed microdosing without prescriber involvement is not advisable — you lose the safety net of clinical monitoring.
The Bottom Line
A microdose of semaglutide is typically a weekly dose below the standard 0.25 mg starting dose, often 0.05-0.1 mg. Microdosing is only available through compounded semaglutide and is used primarily for severe side-effect sensitivity or very gradual acclimation. Microdoses produce minimal weight loss; they are acclimation tools, not therapeutic strategies. Most patients tolerate standard 0.25 mg starting doses well and don’t need microdosing. Discuss with your prescriber before starting any non-standard dosing approach. For more on GLP-1 treatment options, see our hub.
